Next generation biotherapeutics require next generation expression systems. Pichia pastoris has emerged as a valuable alternative to more established platforms for the expression and production of novel protein formats. Traditional prokaryotic expression systems often struggle to produce novel biologics with high purity, quality and yield. As a eukaryotic host organism, Pichia is better able to fold and assemble complex proteins into functional molecules. Expressing soluble secreted product makes recovery and downstream processing easier and more efficient, enabling production of high quality, purity products at high yields.
In this Fierce Biotech webinar we will examine a number of the benefits of Lonza’s , XS® Pichia 2.0 including : speed, simple fermentation regimes, robust and scalable processes that can be tuned according to the specific objectives of a program, helping to advance new drug candidates through the development pipeline. We will examine the benefits of XS® Pichia 2.0 by referencing a number of case studies with different molecule formats.
A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panel.